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Objectives
Renal dysfunction is a significant cause of morbidity and mortality among HIV-positive
individuals. This study evaluated renal dysfunction in a cohort of adults who started antiretroviral
treatment (ART) regardless of CD4 count at three Department of Health (DOH) clinics included in
the HIV Prevention Trials Network 071 (HPTN 071) Population Effect of Antiretroviral Therapy to
Reduce HIV Transmission (PopART) trial.
Methods
A retrospective cohort analysis of routine data for HIV-positive individuals starting ART between
January 2014 and November 2015 was completed. Incident renal dysfunction was defined as an
estimated glomerular filtration rate (eEGFR) < 60 mL/min after ART initiation among individuals
with a baseline (pre-ART) eGFR ≥ 60 mL/min.
Results
Overall, 2423 individuals, with a median baseline CD4 count of 328 cells/lL [interquartile range
(IQR) 195–468 cells/lL], were included in the analysis. Forty-seven individuals had a baseline eGFR
< 60 mL/min. Among 1634 nonpregnant individuals started on a tenofovir-containing ART regimen
and with a baseline eGFR ≥ 60 mL/min, 27 developed an eGFR < 60 mL/min on ART. Regression
analysis showed lower odds of baseline eGFR < 60 mL/min at baseline CD4 counts of > 500 cells/lL
[adjusted odds ratio (aOR) 0.29; 95% confidence interval (CI) 0.11–0.80], 351–500 cells/lL (aOR
0.22; 95% CI 0.08–0.59) and 201–350 (aOR 0.48; 95% CI: 0.24–0.97) compared with baseline CD4
counts < 200 cells/lL.
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Conclusions
This study showed low rates of renal dysfunction at baseline and on ART, with lower rates of baseline
renal dysfunction among individuals with baseline CD4 counts > 200 cells/lL. Strategies that use
baseline characteristics, such as age, to identify individuals at high risk of renal dysfunction on ART
for enhanced eGFR monitoring may be effective and should be the subject of future research.
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Introduction
The number of individuals on antiretroviral therapy
(ART) continues to increase annually [1]. Recent World
Health Organization (WHO) recommendations to start
ART regardless of CD4 cell count in high-burden settings
have been adopted by almost all countries and can be
expected to lead to an increased number of HIV-positive
individuals starting ART at higher CD4 cell counts [2,3].
Renal dysfunction is a well-recognized cause of mor-
bidity and mortality among HIV-positive individuals with
advanced disease and amongst those starting ART [4,5].
In HIV-positive individuals, renal dysfunction may occur
through various mechanisms, including HIV-associated
nephropathy (HIVAN), HIV immune complex kidney dis-
ease, thrombotic microangiopathy and toxicity from cer-
tain ART compounds such as tenofovir disoproxil
fumarate (TDF) [4,6]. Although immune reconstitution
after ART initiation is overall associated with improved
renal function, for those starting therapy with advanced
disease, ART initiation at HIV diagnosis irrespective of
CD4 count may potentially have a negative impact on
renal function through longer exposure to TDF toxicity
[4,5,7], as TDF is a recommended component of first-line
ART globally [8]. Routine monitoring of renal function in
individuals starting TDF using the estimated serum
glomerular filtration rate (eGFR) is desirable, and TDF is
not recommended for individuals with eGFR < 60 mL/
min at the time of ART initiation [9].
Programmatic studies from high-burden settings show
a varying prevalence of baseline renal dysfunction
among individuals starting ART [10–14]. The reported
association between baseline CD4 count and baseline
renal dysfunction also varies, with some studies showing
higher baseline renal dysfunction at lower CD4 counts
[12,13] and other studies showing no association [10,14].
An association has been reported between low CD4
count and renal dysfunction after ART initiation, from
programmatic studies, with median baseline CD4 counts
ranging from 154 to 209 cells/lL. These studies reported
less renal dysfunction following ART initiation among
individuals with baseline CD4 counts > 200 cells/lL com-
pared with lower values [15,16]. Recently published results
from the Strategic timing of antiretroviral treatment
(START) trial showed higher mean eGFR after ART initia-
tion among individuals starting ART at baseline CD4
counts > 500 cells/lL compared with those with baseline
CD4 counts of 350–500 cells/lL [17]. There are, however,
limited data from programmatic studies to confirm these
findings. This study aimed to evaluate the association
between baseline CD4 count and renal dysfunction at
baseline and after ART initiation among adults starting
ART regardless of CD4 count at three Department of
Health (DOH) clinics, included in the HPTN 071 [Popula-
tion Effect of Antiretroviral Therapy to Reduce HIV Trans-
mission (PopART)] trial, in South Africa.
Methods
Study setting
The HPTN 071 PopART study is a community randomized
trial implemented in South Africa and Zambia. A full
description of the PopART trial design has previously
been published [18]. For PopART, a community was
defined as the catchment population of a DOH primary
health care (PHC) clinic. PopART communities were ran-
domly allocated to one of three arms: A, B or C. Arm A
communities received the full intervention package,
which included community HIV prevention services
delivered by a cadre of community workers named Com-
munity HIV Care Providers (CHiPs) and ART regardless of
CD4 count at the local DOH clinic. Arm B communities
received the CHiP intervention with ART as per in-coun-
try guidelines, while Arm C communities received stan-
dard care interventions only.
Two clinics were in an urban area and have been named
‘Metro 1’ and ‘Metro 2’; one clinic was in a rural area and
has been named ‘Rural’. All three study clinics offered the
same package of PHC services. ART services at the three
study clinics were provided according to provincial DOH
ART guidelines [19], with the exception that all three study
clinics offered ART regardless of CD4 count from 1 January
2014, before the provincial DOH ART guidelines changed
to ART regardless of CD4 count in October 2016, as defined
in the trial protocol [19]. As part of routine care, all
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individuals starting ART were recorded in the electronic
HIV programme monitoring system, Tier.net [20]. In accor-
dance with South African guidelines, a fixed-dose combi-
nation tablet of TDF, emtricitabine and efavirenz (TEE) was
used as the first-line ART regimen of choice. All laboratory
services were provided by the centralized regional National
Health Laboratory Services (NHLS) with daily pick-up of
specimens from all PHC clinics. TDF was contraindicated in
individuals with baseline eGFR < 50 mL/min in whom
zidovudine (ZDV), stavudine (d4T) and abacavir (ABC) were
recommended first-line alternatives [21]. For individuals
starting TDF, serum creatinine used for eGFR estimation
was measured prior to ART initiation, at 1, 4 and 12 months
after initiating therapy, and annually thereafter [21].
Cohort overview and definitions
A retrospective cohort study design was utilized. All HIV-
positive adults (≥ 18 years old) recorded in Tier.net [20] as
having started ART at the three study clinics between 1 Jan-
uary 2014 and the end of November 2015 were screened for
inclusion. Individuals were excluded from the analysis if
they did not have a recorded baseline CD4 count.
Baseline CD4 count was defined as the most recent CD4
count recorded in the 6 months prior to starting ART. Base-
line eGFR was estimated from the most recent serum crea-
tinine (SCR) measurement recorded in the 6 months prior to
starting ART. For this analysis, American National Kidney
Foundation criteria were used to define levels of renal dys-
function, that is, mild (eGFR 60–89 mL/min), moderate
(eGFR 30–59 mL/min) or severe (eGFR < 30 mL/min), to
best align our data with other published data [22]. The mod-
erate and severe renal dysfunction categories were com-
bined (eGFR < 60 mL/min) for analysis of both baseline
renal dysfunction (eGFR < 60 mL/min) and incident renal
dysfunction (eGFR < 60 mL/min). The definition of incident
eGFR < 60 mL/min was based on one recorded
eGFR < 60 mL/min. Baseline tuberculosis (TB) was defined
as being on TB treatment at the time of ART start.
Attrition was defined as being 3 months late for a
scheduled clinic appointment and included all individuals
no longer in care as a result of loss to follow-up (LTFU)
or death. Death and LTFU were not analysed separately in
this study, as death was not consistently recorded in
Tier.net. Transfer out (TFO) was defined as elective trans-
fer of an individual to another ART clinic documented in
Tier.net.
All individuals were followed up for a minimum of
6 months until the end of May 2016 (the date of adminis-
trative censor) or until the date of attrition or TFO if that
occurred earlier. For the analysis of incident renal dys-
function, as a binary variable, individuals were censored
after the first episode of incident renal dysfunction
(eGFR < 60 mL/min). All analyses of eGFR after ART initi-
ation (on ART eGFR) were restricted to individuals starting
a TDF-containing ART regimen (Fig. 1). Individuals with
baseline TB were included in analysis of on-ART eGFR.
Data sources and management
Routine DOH and NHLS data were used in this study.
Unless otherwise stated, all data were extracted from Tier.-
net [20]. Data for SCR results were extracted from the
NHLS database and linked to Tier.net data using the DOH
unique identifier. eGFR was calculated from SCR, age and
sex using the Modification of Diet in Renal Disease Study
(MDRD) Study equation [eGFR = 175 9 standardized
SCR1.154 9 age0.203 9 1.212 (if black) 9 0.742 (if
Total individuals screened 
= 2593  
2423 with reported baseline CD4 
count  included in baseline analysis 
2014 non-pregnant 
individuals with baseline 
EGFR reported included in 
analysis of baseline EGFR 
<60mL/min as a binary 
variable.  
1772 individuals started 
on tenofovir, with 
reported baseline and on-
ART EGFR included in 
analysis of mean on-ART 
EGFR as a connuous 
variable.  
1651 non-pregnant 
individuals started on 
tenofovir, with reported 
baseline and on-ART EGFR 
and baseline 
eGFR≥60ml/min included 
in analysis of on-ART EGFR 
<60mL/min as a binary 
variable  
Fig. 1 Overview of individuals included in the respective analyses.
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female)] [23], with omission of the racial category factor.
This method for estimating eGFR from serum creatinine
has been previously validated in the South African context
and shown to be more accurate than the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equations
[16,24,25]. MDRD is the method of choice for estimating
eGFR from results of the current serum creatinine assay
used by the NHLS in South Africa and at the clinics
included in this study [21,26]. A sensitivity analysis using
eGFR calculated with the CKD-EPI equation, without the
race factor, as recommended by Seape et al. [25], was also
completed for this study.
Creatinine data missing from the NHLS data extracts
were, where available, extracted from clinic folders. Data
from the DOH electronic TB monitoring system, ETR.net,
were used to identify individuals with baseline TB. All
data fields and data linkages were reviewed for complete-
ness and accuracy.
Analysis
Standard descriptive analyses including absolute numbers
and proportions were used to describe baseline character-
istics. The similarity of baseline characteristics across
baseline CD4 count categories was analysed using v2 and
Kruskal–Wallis tests. Logistic regression was used to
model the association of baseline characteristics with
baseline renal dysfunction. Mixed effects linear regression
was performed using a model with random intercept at
the participant level with random slope for time from
starting ART to eGFR measurement. Time-to-event analy-
ses for incident eGFR < 60 mL/min as a binary variable
were performed using Kaplan–Meier survival estimates in
nonpregnant individuals with baseline eGFR ≥ 60 mL/
min. Cox regression was used in analysis of baseline
characteristics associated with hazard of eGFR < 60 mL/
min on ART. This analysis was restricted to nonpregnant
individuals and those with baseline eGFR ≥ 60 mL/min.
Women pregnant at the time of starting ART were
excluded from the analysis of baseline on-ART
eGFR < 60 mL/min in view of increases in eGFR levels
during pregnancy of up to 50% [27]. Within this group
of participants, a sensitivity analysis using eGFR calcu-
lated with the CKD-EPI equation without the race factor
was performed.
The same baseline characteristics, namely age, sex,
CD4 count, eGFR, TB status, clinic where treatment was
received, year in which ART started, pregnancy at base-
line and previous ART exposure of greater than 3 months
duration were included in all multivariate models unless
otherwise stated. Baseline characteristics for inclusion in
multivariate modelling were selected primarily on the
basis of clinical significance and data availability. Likeli-
hood ratio tests were used to assess the regression model
goodness of fit. All the multivariate models showed a
good fit (P < 0.05). For Cox regression, Schoenfeld resid-
uals were used to test the proportional hazard assump-
tions. The reference category for categorical variables
was selected by using the category with the largest sam-
ple size or based on clinical significance. Comparison of
baseline characteristics between individuals excluded
from analyses because of missing eGFR results and those
retained in analyses was performed using logistic regres-
sion. Logistic regression was also used to compare base-
line characteristics of individuals retained in the study
cohort and those experiencing attrition or TFO. Analyses
were performed using STATA version 14 (StataCorp LP,
College Station, TX).
Ethics
The HPTN 071 (PopART) trial has been approved by the
Stellenbosch University Health Research Ethics Committee
(SU HREC) (Ref. No. N12/11/074) and the London School
of Hygiene and Tropical Medicine Research Ethics Com-
mittee (Ref. no. 6326). All HIV-positive individuals start-
ing ART outside of provincial ART guidelines provided
informed consent. Additional SU HREC approval for the
use of individual-level DOH data in this study, including
a waiver for informed consent, was received from SU
HREC (Ref. no. N12/11/074A) as well as from the Western
Cape Government (Ref. no. WC_2015RP51_715) and City
of Cape Town (Ref. no 10529) research committees.
Results
Baseline characteristics
Overall, 2593 individuals were screened for study inclu-
sion; 170 (6.6%) were excluded because of missing base-
line CD4 cell counts, leaving 2423 (93.4%) individuals
included in the baseline analysis (Fig. 1 and Table 1). The
median baseline CD4 count was 328 cells/lL [interquar-
tile range (IQR) 195–468 cells/lL]. The number of indi-
viduals in the baseline CD4 cell categories varied between
631 (26.0%) for CD4 counts of 0–200 cells/lL and 502
(20.7%) for CD4 counts > 500 cells/lL. The median age
was 31 years (IQR 26–38 years), and the majority of par-
ticipants (1643; 67.8%) were women. Baseline eGFR was
available for 2141 of 2423 (88.4%) individuals. The med-
ian baseline eGFR was 110.5 mL/min (IQR 93.5–131.9
mL/min). A total of 47 (1.9%), 394 (16.3%) and 1700
(70.2%) individuals had baseline eGFR < 60, 60–89 and
≥ 90 mL/min, respectively.
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Baseline factors associated with baseline
eGFR < 60 mL/min
Univariate and multivariate logistic regression analyses of
the association between baseline characteristics and base-
line eGFR < 60 mL/min among 2014 nonpregnant indi-
viduals (Fig. 1) with a reported baseline CD4 count are
shown in Table 2. In this subset of individuals, 47 of
2014 (2.3%) had a baseline eGFR < 60 mL/min. The
adjusted odds ratios (aORs) of baseline eGFR < 60 mL/
min across baseline CD4 count categories were 0.29 [95%
confidence interval (CI) 0.11–0.80] for CD4 counts
> 500 cells/lL, 0.22 (95% CI 0.08–0.59) for CD4 counts
of 351–500 cells/lL and 0.48 (95% CI 0.24–0.97) for CD4
counts of 201–350 cells/lL compared with CD4 counts of
0–200 cells/lL. Baseline eGFR < 60 mL/min was also
more common in individuals aged > 35 years, with aORs
of 3.38 (95% CI 1.64–6.95) for ages 36–45 years and 6.40
(95% CI 3.06–13.37) for ages > 45 years compared with
individuals aged ≤ 35 years. Baseline eGFR < 60 mL/min
was more common among men (aOR 1.99; 95% CI 1.08–
3.66) than women. There were no other baseline variables
associated with baseline eGFR < 60 mL/min.
Baseline factors associated with on-ART eGFR
A total of 651 (26.9%) of the 2423 individuals included
in the baseline analysis were excluded from the analysis
of mean eGFR after ART initiation for the following rea-
sons: (1) missing baseline eGFR (282 individuals; 43.3%);
(2) started on an ART regimen that did not contain TDF
or unknown baseline ART regimen (53 individuals; 8.1%)
and (3) no reported eGFR after ART initiation (on-ART
eGFR) (316 individuals; 48.5%). The remaining 1772
(73.1%) individuals were included in the analysis of on-
ART eGFR after ART initiation and were followed up for
a median of 12.1 (IQR 7.9–16.9) months, during which
time 329 (18.6%) experienced attrition and 85 (4.8%)
experienced TFO.
The mean on-ART eGFR was 114.6 mL/min (95% CI
113.6–115.6 mL/min). Multivariate mixed effects linear
regression showed that, compared with those with
Table 1 Baseline characteristics
CD4 count at baseline
Total P value0–200 cells/lL 201–350 cells/lL 351–500 cells/lL > 500 cells/lL
Baseline CD4 category [n (%)] 631 (26.0) 708 (29.2) 582 (24.0) 502 (20.7) 2423
Age (years)
[median (IQR)] 33 (29.0–40.0) 31 (25.0–37.0) 31 (26.0–37.0) 30 (25.0–37.0) 31 (26.0–38.0) < 0.001
Age category [n (%)]
18–25 years 79 (12.5) 179 (25.3) 142 (24.4) 134 (26.7) 534 (22.0) < 0.001
26–35 years 312 (49.6) 311 (43.9) 272 (46.7) 227 (45.2) 1122 (46.3)
36–45 years 167 (26.5) 138 (19.5) 109 (18.7) 87 (17.3) 501 (20.7)
46–55 years 57 (9.0) 63 (8.9) 46 (7.9) 44 (8.8) 210 (8.7)
> 55 years 17 (2.7) 17 (2.4) 13 (2.2) 10 (2.0) 57 (2.3)
Gender [n (%)]
Female 355 (56.3) 463 (65.4) 421 (72.3) 404 (80.5) 1643 (67.8) < 0.001
Male 276 (43.7) 245 (34.6) 161 (27.7) 98 (19.5) 780 (32.1)
Pregnant at ART start [n (%)] 14 (3.9) 39 (8.4) 41 (9.7) 48 (11.9) 142 (8.6) < 0.001
Baseline TB [n (%)] 162 (25.7) 56 (7.9) 41 (6.7) 26 (5.2) 285 (11.8) < 0.001
Clinic [n (%)]
Metro 1 88 (13.9) 113 (15.9) 126 (21.7) 127 (25.3) 454 (18.7) < 0.001
Metro 2 299 (47.4) 301 (42.5) 231 (39.7) 191 (38.1) 1022 (42.2)
Rural 244 (38.7) 294 (41.5) 225 (38.7) 184 (36.7) 947 (39.1)
Previous ART > 3 months [n (%)] 27 (4.3) 10 (1.4) 7 (1.2) 5 (1.0) 49 (2.0) 0.005
ART start year [n (%)]
2014 161 (25.5) 208 (29.4) 160 (27.5) 161 (32.1) 690 (28.5) 0.091
2015 470 (74.2) 500 (70.6) 422 (72.5) 341 (67.9) 1733 (71.5)
Baseline eGFR (mL/min)
Median (IQR) 106.7 (89.5–130.6) 110.6 (94.3–129.7) 111.1 (93.1–131.7) 112.9 (96.5–134.1) 110.5 (93.5–131.9) 0.0186
< 60 mL/min [n (%)] 24 (3.8) 14 (1.9) 4 (0.7) 5 (1.0) 47 (1.9) < 0.001
60–89 mL/min [n (%)] 114 (18.1) 106 (14.9) 100 (17.2) 74 (14.7) 394 (16.3)
≥ 90 mL/min [n (%)] 399 (63.3) 506 (71.4) 418 (71.8) 377 (75.1) 1700 (70.2)
Missing [n (%)] 94 (14.8) 82 (11.7) 60 (10.3) 46 (9.2) 282 (11.6)
This table includes all 2423 participants included in the study sample. v2 and Kruskal–Wallis tests were used to measure the heterogeneity of baseline
characteristics across the baseline CD4 count categories. Overall, there was significant heterogeneity across baseline CD4 count categories. American
Kidney Foundation definitions were used for defining renal function using estimated glomerular filtration rate (eGFR). Moderate and severe renal dys-
function was defined as eGFR < 60 mL/min; mild renal dysfunction was defined as eGFR = 60–89 mL/min; normal renal function was defined as
eGFR ≥ 90 mL/min.
ART, antiretroviral therapy; IQR, interquartile range; TB, tuberculosis.
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baseline eGFR ≥ 90 mL/min, mean on-ART eGFR was
37.49 mL/min (95% CI 28.52–46.46 mL/min) lower
among individuals with baseline eGFR < 60 mL/min and
22.47 mL/min (95% CI 19.34–25.60 mL/min) lower
among individuals with baseline eGFR 60–89 mL/min
(Table 3). Mean on-ART eGFR was 20.56 mL/min (95% CI
15.57–25.55 mL/min) greater among women pregnant at
baseline and 6.80 mL/min (95% CI 3.67–9.92 mL/min)
lower among individuals attending the Metro 2 clinic
compared with Metro 1. There was no difference in mean
eGFR when comparing individuals treated at the Rural
clinic and Metro 1. There was a mean change in on-ART
eGFR of 0.38 mL/min (95% CI 0.53 to 0.22 mL/min)
per month of follow-up.
Baseline factors associated with on-ART incident
eGFR < 60 mL/min
For analysis of incident eGFR < 60 mL/min, 106 women
who were pregnant at baseline were excluded, leaving a
sample size of 1665. Kaplan–Meier estimates showed
higher rates of on-ART eGFR < 60 mL/min over time at
lower baseline CD4 counts (P = 0.011) (Fig. 2). There
were 33 incident cases of eGFR < 60 mL/min occurring
in 1665 individuals during 1750 person-years (PY), giv-
ing an incidence rate (IR) of 1.9/100 PY (95% CI 1.3–
2.6/100 PY) (Table 4). The IR of eGFR < 60 mL/min was
highest during the first 6 months of ART (IR 2.3/100
PY; 95% CI 1.99–2.66/100 PY) compared with longer
durations of ART; however, this difference was not sta-
tistically significant. The analysis restricted to 1634
nonpregnant individuals with baseline eGFR ≥ 60 mL/
min showed that there were 27 incident cases of
eGFR < 60 mL/min during 1722 person-years (PY) of
follow-up (IR 1.6/100 PY; 95% CI 1.1–2.3/100 PY)
(Table 4).
All individuals with recorded incident on-ART eGFR had
multiple on-ART eGFR laboratory results. However, among
the 27 individuals who had an incident eGFR < 60 mL/
min in the subset of individuals included in multivariate
analysis, only five (18.5%) had a further result that showed
an eGFR < 60 mL/min recorded after their initial
eGFR < 60 mL/min result. Of these five, one changed to a
non-TDF-containing ART regimen and four remained on
TDF. Four of 5 (80%) of these individuals, including the
one that changed ART regimen, had a last recorded
eGFR < 60 mL/min. Eight of the 27 (29.6%) had no further
recorded eGFR after one episode of eGFR < 60 mL/min. In
the remaining 14 cases, there was only one recorded eGFR
of < 60 mL/min, with at least one subsequent eGFR
> 60 mL/min recorded. Thirteen of these 14 (92.9%) indi-
viduals remained on TDF during the follow-up period.
When the analysis was further restricted to 1320 non-
pregnant individuals with baseline eGFR ≥ 90 mL/min,
there were only 15 incident cases of eGFR < 60 mL/min
(IR 1.1/100 PY; 95% CI 0.6–1.8/100 PY). Notably, when
the analysis was limited to this group with normal baseline
eGFR, there were no incident cases of eGFR < 60 mL/min
among individuals with baseline CD4 counts > 500 cells/
lL.
Multivariate Cox regression, which included 27 inci-
dent cases of eGFR < 60 mL/min among 1634
Table 2 Baseline factors associated with baseline renal dysfunction
Baseline factor
Number of events/number of
eligible individuals (%)
Crude odds ratio
(95% CI) P value
Adjusted odds ratio
(95% CI) P value
Baseline CD4 count (cells/lL) > 500 5/409 (1.2) 0.19 (0.07, 0.56) < 0.001 0.29 (0.11, 0.8) 0.003
351–500 4/486 (1.0) 0.17 (0.06, 0.47) 0.22 (0.08, 0.59)
201–350 14/596 (2.4) 0.38 (0.18, 0.83) 0.48 (0.24, 0.97)
0–200 25/523 (4.8) 1 1
Gender Male 29/670 (4.3) 2.99 (1.68, 5.34) < 0.001 1.99 (1.08, 3.66) 0.027
Female 20/1344 (1.5) 1 1
Age at ART start (years) 18–35 14/1347 (1.0) 1 < 0.001 1 < 0.001
36–45 18/431 (4.2) 4.14 (2.04, 8.41) 3.38 (1.64, 6.95)
> 45 17/236 (7.2) 7.39 (3.59, 15.21) 6.40 (3.06, 13.37)
Clinic Metro 1 15/852 (1.8) 1 0.233 1 0.186
Metro 2 23/786 (2.9) 1.68 (0.87, 3.25) 1.96 (0.93, 4.11)
Rural 11/376 (2.9) 1.68 (0.76, 3.69) 1.84 (0.77, 4.39)
Baseline TB TB 8/237 (3.4) 1.55 (0.84, 2.88) 0.175 0.97 (0.5, 1.87) 0.920
Previous ART > 3 months Yes 1/40 (2.5) 1.03 (0.14, 7.64) 0.978 0.86 (0.11, 6.68) 0.889
Year of ART start 2014 15/584 (2.6) 0.41 (0.37, 0.45) 0.801 0.78 (0.38, 1.56) 0.489
2015 34/1430 (2.4) 1 1
The table includes a total of 2014 nonpregnant individuals with recorded baseline CD4 count and baseline estimated glomerular filtration rate (eGFR).
Women who were pregnant at baseline were excluded because of changes in eGFR associated with pregnancy. Age categories 18–25 and 26–35 years
were combined and age categories 46–55 and > 55 years were combined for the regression analysis because of small numbers of events in some age
groups. P values were calculated using likelihood ratios.
ART, antiretroviral therapy; CI, confidence interval; TB, tuberculosis.
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nonpregnant individuals with baseline eGFR ≥ 60 mL/
min (Table 5), showed a lower hazard ratio of
eGFR < 60 mL/min in higher baseline CD4 categories
compared with baseline CD4 count < 200 cell/lL, but
this finding was not statistically significant. There was a
higher hazard ratio of incident eGFR < 60 mL/min
among individuals with a baseline eGFR of 60–89 mL/
min [adjusted hazard ratio (aHR) 2.62; 95% CI 1.17–5.83]
compared with those with baseline eGFR ≥ 90 mL/min
and among individuals aged > 45 years (aHR 3.25; 95%
CI 1.30–8.14) compared with individuals aged ≤ 35 years.
No other baseline characteristics were associated with
incident eGFR < 60 mL/min.
Sensitivity analysis using the CKD-EPI formula
When eGFR calculated with the CKD-EPI equation was
used, the mean on-ART eGFR was 118.1 mL/min (95% CI
117.4–118.8 mL/min) and the number of incident
eGFR < 60 mL/min cases reduced from 27 to 17 (IR 0.88/
100 PY; 95% CI 0.06–0.14/100 PY). Multivariate analysis
also did not show an association between baseline CD4
count or any other baseline factors and incident
eGFR < 60 mL/min calculated using the CKD-EPI equation.
Analysis of missing data
Logistic regression using the full model showed increased
rates of missing baseline eGFR results at higher baseline
CD4 counts > 500 cells/lL (aOR 1.54; 95% CI 1.04–2.26)
compared with baseline CD4 counts ≤ 200 cells/lL. Indi-
viduals with missing baseline eGFR results were less
likely to be male (aOR 0.71; 95% CI 0.55–0.93) and more
likely to attend the Rural clinic (aOR 1.54; 95% CI 10.01–
2.33) rather than Metro 1. Individuals excluded from fol-
low-up analysis because of missing on-ART eGFR were
more likely to have a baseline CD4 count of 201–
350 cells/lL (aOR 1.35; 95% CI 1.00–1.83). Individuals
experiencing attrition or TFO were less likely to have
started ART in 2015 (aOR 0.60; 95% CI 0.46–0.79) as
opposed to 2014; less likely to be aged 36–45 years
(aOR 0.72; 95% CI 0.55–0.97) or > 45 years (aOR 0.49;
Table 3 Baseline factors associated with on-antiretroviral therapy (ART) estimated glomerular filtration rate (eGFR)
Estimated eGFR Crude coefficient (95% CI) Adjusted coefficient (95% CI)
Baseline CD4 count
> 500 cells/lL 2.72 (1.3, 6.74) 0.552 0.79 (4.38, 2.8) 0.974
350–500 cells/lL 1.94 (1.93, 5.81) 0.13 (3.56, 3.29)
200–350 cells/lL 1.28 (2.4, 4.97) 0.17 (3.42, 3.08)
0–200 cells/lL 1 1
Baseline eGFR
< 60 mL/min 27.08 (30.26, 23.91) < 0.001 37.49 (46.46, 28.52) < 0.001
60–89 mL/min 44.46 (53.74, 5.17) 22.47 (25.60, 19.34)
≥ 90 mL/min 1 1
Gender
Male 4.65 (7.57, 1.73) 0.002 1.27 (1.42, 3.96) 0.356
Female 1 1
Age category
18–35 years 1 < 0.001 1 < 0.001
36–45 years 14.89 (18.16, 11.61) 10.3 (13.36, 7.25)
> 45 years 22.35 (26.48, 18.22) 7) 13.3 (17.22, 9.38)
Pregnant at baseline
Yes 25.99 (20.51, 31.47) < 0.001 20.56 (15.57, 25.55) < 0.001
Clinic
Metro 1 1 < 0.001 1 < 0.001
Metro 2 7.43 (10.45, 4.4) 6.80 (9.92, 3.67)
Rural 2.15 (5.77, 1.48) 2.09 (5.69, 1.52)
Baseline TB
Yes 1.67 (1.63, 4.97) 0.382 6.71 (17.38, 3.96) 0.106
Previous ART of > 3 months
Yes 10.44 (22.63, 1.75) 0.093 2.45 (0.52, 5.42) 0.218
Year of ART start
2014 1.06 (3.96, 1.83) 0.471 1.67 (1.35, 4.68) 0.279
2015 1 1
Time on ART
Change/month 0.36 (0.51, 0.21) < 0.001 0.38 (0.53, 0.22) < 0.001
Modelling included 1772 individuals with reported baseline and on-ART estimated glomerular filtration rate (eGFR), including pregnant women. The
individual unique identifier was used as the panel variable. For categorical variables, the coefficient represents the difference in mean eGFR in mL/min
from baseline compared with the reference category.
CI, confidence interval; TB, tuberculosis.
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95% CI 0.33 0.72) as opposed to ≤ 35 years and more
likely to be treated at the Metro 2 clinic (aOR 1.46; 95%
CI 1.09–1.95) rather than at Metro 1.
Discussion
This is one of the first studies to evaluate the association
between baseline CD4 count and renal dysfunction in the
context of routine provision of ART regardless of CD4
count in a high-burden programmatic setting. Probably as
a result of this expanded ART access, the baseline median
CD4 count in this study (328 cells/lL) was higher than that
reported in previous studies from high-burden settings
[13,16,28]. This study found a low baseline prevalence rate
of eGFR < 60 mL/min (1.9%), similar to that in a large
published study from Zambia [29]. Also similar to previous
studies [13,16,28], this study showed lower baseline preva-
lence of renal dysfunction at baseline CD4 counts
> 200 cells/lL and among younger individuals.
Similar to other studies, this study showed a small
mean decline in eGFR over time on tenofovir [16]. The
overall incidence rate of eGFR < 60 mL/min (1.9 cases/
100 PY) was lower than that reported in a previous study
(5.9 cases/100 PY) with a lower baseline median CD4
count that reported on the same endpoint [16]. Also in
contrast to previous studies, this study did not find an
association between baseline CD4 count and average
eGFR or renal dysfunction after ART initiation after
adjustment for key baseline characteristics [10,17]. Nota-
bly, analysis of incident eGFR < 60 mL/min – restricted
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Fig. 2 Kaplan–Meier estimates of estimated glomerular filtration rate (eGFR) < 60 mL/min on antiretroviral therapy (ART) in participants with
baseline eGFR ≥ 60 mL/min. These participants included 1634 individuals with baseline eGFR ≥ 60 mL/min. Log-rank test for difference in
Kaplan Meier estimates by CD4 category: P = 0.011.
Table 4 On-antiretroviral therapy (ART) incident estimated glomerular filtration rate (eGFR) < 60 mL/min by baseline eGFR category
Baseline CD4
count (cells/lL)
All baseline eGFR Baseline eGFR ≥ 60 mL/min Baseline eGFR ≥ 90 mL/min
No. of
events/person
time IR/100 PY
No. of
events/person
time IR/100 PY
No. of
events/person
time IR/100 PY
Sample size 1665 1634 1320
IR 0–200 16/418 3.8 (2.3, 6.2) 13/409 3.2 (1.8–5.5) 8/320 2.5 (1.2, 4.9)
201–350 9/550 1.6 (0.9, 3.1) 6/538 1.1 (0.5–2.5) 4/443 0.9 (0.3, 2.4)
301–500 4/425 0.9 (0.4, 2.5) 4/423 0.9 (0.4–2.5) 3/343 0.9 (0.3, 2.7)
> 500 4/357 1.1 (0.4, 2.9) 4/353 1.1 (0.4–3) 0/295 0 (0, 0)
All 33/1750 1.9 (1.3, 2.6) 27/1722 1.6 (1.1–2.3) 15/1401 1.1 (0.6, 1.8)
An event is defined as eGFR < 60 mL/min. Baseline eGFR cut-offs were selected to align to American Kidney Foundation definitions; eGFR ≥ 60 mL/
min was considered to represent normal eGFR or mild renal impairment and eGFR ≥ 90 mL/min normal renal function.
PY, person-years; IR, incidence rate.
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to individuals with a normal baseline renal function –
showed a low incidence rate of eGFR < 60 mL/min of
1.1 cases/100 PY (95% CI 0.6–1.8 cases/100 PY) and no
incident cases among individuals with baseline CD4
counts > 500 cells/lL. As in previous studies, this study
showed baseline renal dysfunction to be a strong predic-
tor of on-ART renal dysfunction [13,16,29]. The number
of individuals who changed from a TDF-containing regi-
men was small, and the data showed good recovery of
renal function in the majority of individuals experiencing
eGFR < 60 mL/min on ART.
Monitoring of renal function in high-burden settings is
challenging [13,30]. TDF continues to be widely used for
first-line ART in high-burden regions, and in the absence
of an affordable alternative, strategies to improve eGFR
monitoring in individuals on TDF are needed [8,21] Teno-
fovir alafenamide (TAF) is a tenofovir prodrug, with
reported lower risk of renal toxicity [31–33]. However,
TAF interacts with rifampicin, which is used for TB treat-
ment, which makes the introduction of this drug in
resource-limited settings with a high burden of TB chal-
lenging [9,34,35]. Management of renal function on ART
is further challenged by limited access to laboratory ser-
vices in resource-limited settings, and further research to
evaluate the potential of more accessible point-of-care
technology for monitoring renal function is needed [30].
In settings where relevant laboratory services are avail-
able, nonadherence to eGFR monitoring is widely
reported [30,36].
This study used the MDRD equation without the race
factor for calculation of the primary endpoint with a sen-
sitivity analysis using the CKP-EPI equation without the
race factor. These analyses showed an overall mean on-
ART eGFR of 114 and 118 mL/min, respectively. The
MDRD equation without the race factor is the current
preferred method for calculating eGFR used by the NHLS
in South Africa [26]. Similar to previous studies, there
were significant differences in the results when using
these two equations. A previous study from South Africa
showed cystatin C-based estimations to be the most accu-
rate for calculating eGFR [25]. Of the creatinine-based
formulae, both MDRD and CKP-EPI equations, both with-
out the race factor, overestimated eGFR by 14.2 and
15.3%, respectively [25]. Cystatin C-based estimations are
currently not affordable for routine use in many high-
burden settings [25].
These reported inaccuracies in the current methods
commonly used for estimating eGFR are concerning and
the strategy for eGFR monitoring in high-burden settings
needs revision. Models that use individual-level factors
such as age, sex, body mass index, diabetes status, blood
pressure, serum creatinine and urine protein to identify
individuals at high risk of renal dysfunction are used in
some contexts [37]. Published studies suggest that there
is still a need to further develop and validate these ‘high-
risk’ models in high-burden settings, where they might be
successfully integrated in routine clinical care as part of
a differentiated care approach [36,37].
Despite a well-established ART service in the Western
Cape since 2004, and the provision of ART regardless of
CD4 count in the PopART intervention since January 2014,
a significant proportion (26%) of this cohort presented
with baseline CD4 counts < 200 cells/lL. These data sug-
gest that offering ART regardless of CD4 count, with
increased numbers of individuals starting ART at higher
CD4 counts, will have a positive impact on baseline renal
function among individuals starting ART. Although these
data did not show an association between baseline CD4
count and renal dysfunction in the primary analysis, the
absence of incident renal dysfunction among individuals
Table 5 Baseline factors associated with on-antiretroviral therapy
(ART) incident estimated glomerular filtration rate (eGFR) < 60 mL/
min among individuals with baseline eGFR ≥ 60 mL/min
Crude hazard
ratio (95% CI) P value
Adjusted hazard
ratio (95% CI) P value
Baseline CD4 count
> 500 cells/lL 0.36 (0.12, 1.11) 0.056 0.41 (0.13, 1.3) 0.131
351–500 cells/lL 0.3 (0.1, 0.92) 0.35 (0.11, 1.1)
201–350 cells/lL 0.35 (0.13, 0.93) 0.38 (0.14, 1.03)
0–200 cells/lL 1 1
Baseline eGFR
60–89 mL/min 3.46 (1.62, 7.39) 0.002 2.62 (1.17, 5.83) 0.019
≥ 90 mL/min 1 1
Gender
Male 1.46 (0.68, 3.15) 0.339 1.08 (0.48, 2.42) 0.845
Female 1 1
Age category
18–35 years 1 0.008 1 0.049
36–45 years 1.63 (0.61, 4.35) 1.24 (0.46, 3.39)
> 45 years 4.33 (1.83, 10.29) 3.25 (1.30, 8.14)
Clinic
Metro 1 1 0.854 1 0.805
Metro 2 0.86 (0.37, 2.01) 0.74 (0.26, 2.12)
Rural 0.74 (0.25, 2.17) 0.68 (0.19, 2.39)
Baseline TB
Yes 1.61 (0.7, 3.67) 0.261 1.27 (0.54, 3.04) 0.583
Previous ART of > 3 months
Yes 3.2 (0.43, 23.61) 0.253 1.77 (0.23, 13.77) 0.588
Year of ART start
2014 0.93 (0.41, 2.12) 0.868 1.11 (0.39, 3.18) 0.843
2015 1 1
Nonpregnant Individuals with baseline eGFR < 60 mL/min were
excluded from the analysis, and the model includes 1634 individuals
with reported baseline eGFR ≥ 60 mL/min. Women who were pregnant
at baseline were excluded because of changes in eGFR associated with
pregnancy. The baseline category with the largest sample size was used
as the reference. There were no incident eGFR < 60 mL/min cases
among individuals reported to be pregnant at baseline; therefore, this
variable was omitted from regression analysis. Age categories 46–55 and
> 55 years were combined as > 45 years because of the limited sample
size.
CI, confidence interval; TB, tuberculosis.
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with baseline CD4 > 500 cells/lL in analysis restricted to
individuals with normal baseline renal function is promis-
ing and should be further evaluated in larger studies.
Strengths and weaknesses
This study presents high-quality routine data from three
clinics providing ART regardless of CD4 count, ahead of
recent changes in WHO and national ART guidelines. The
routine data used also benefited from data quality
improvement interventions during the PopART interven-
tion. The study has been a joint undertaking between
researchers and clinical staff, ensuring that the analysis
and interpretation of the data correctly reflect clinical
activities. The study does, however, have a number of
weaknesses that should be considered. Individual-level
factors, not recorded in the routine data, such as presence
of diabetes and other comorbidities, may have confounded
the study findings. In addition, although the three study
clinics were similar in terms of structure and service
delivery, health systems factors, which were not measured,
may also have confounded study findings. Notably,
among 27 individuals with incident eGFR < 60 mL/min,
29% did not have another eGFR recorded after a recorded
eGFR < 60 mL/min, possibly as the result of the individu-
als being referred to another facility or hospital for ongo-
ing care. There were significant amounts of missing data
and attrition from ART care. Individuals excluded because
of missing baseline eGFR were more likely to have higher
baseline CD4 counts and inclusion of these individuals in
the study sample could have resulted in lower rates of
renal dysfunction being reported. There was also a limited
sample size and follow-up person time, which may have
reduced the validity of several findings, such as the asso-
ciation between baseline CD4 count and incident
eGFR < 60 mL/min, and the results of the sensitivity anal-
ysis. Follow-up was censored at the first recorded event of
eGFR < 60 mL/min; this precluded the study from report-
ing on subsequent additional episodes of eGFR < 60 mL/
min in affected individuals, thereby potentially resulting
in underreporting of the incidence of renal dysfunction
after the first 6 months of ART. Comparison of both the
prevalence of baseline eGFR < 60 mL/min and the inci-
dence of eGFR < 60 mL/min after ART initiation between
this study and other published studies was hampered by
extensive heterogeneity of the definition of renal dysfunc-
tion across studies.
Conclusions
Overall, this study showed low rates of renal dysfunction
at baseline and on-ART in a cohort of individuals started
on TDF and suggests high durability for tenofovir as
first-line ART with a small decline in mean eGFR over
time. The study showed a lower prevalence of baseline
eGFR < 60 mL/min at higher CD4 counts and no associa-
tion between baseline CD4 count and incident on-ART
eGFR < 60 mL/min. The study did, however, observe
higher rates of incident renal dysfunction among older
individuals and those with mild baseline dysfunction. Use
of differentiated models of ART care, in which ‘high-risk’
models are employed to identify individuals at high risk
of renal dysfunction, may be an effective way to improve
renal monitoring in high-burden settings, and this should
be the subject of ongoing research.
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